Radionetics Oncology
38 employees
Biotech/Pharma
Series A · $82.5M
Company details
Team Size38
IndustryBiotech/Pharma
Funding
Total raised
$82.5M
Last stage
Series A
Investors
DCVC Bio
Total raised
$82.5M
Last stage
Series A
Investors
R. Scott Struthers
Founder of Radionetics Oncology and founder/CEO of Crinetics Pharmaceuticals (Nasdaq: CRNX). Radionetics spun out of Crinetics, leveraging its nonpeptide drug discovery platform.
Ana Kusnetzow
Founding member of Radionetics and co-founder of Crinetics Pharmaceuticals. Co-led the Crinetics discovery program that gave rise to the nonpeptide targeted radiotherapeutics platform underlying Radionetics.
Brett Ewald
Founding member of Radionetics with 20 years of oncology experience. Previously SVP of Development and Corporate Strategy at DNAtrix and held leadership roles at Novartis Oncology.
No applications, no recruiter spam. Just the intro.
A few questions to make sure this role is the right shape for you. Two minutes.
I write the intro, send it to the founder, and handle the back-and-forth.
If they’re a yes, I book the chat. You show up — that’s the whole job-hunt.